2seventy bio (NASDAQ:TSVT – Get Free Report) and MorphoSys (NASDAQ:MOR – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for 2seventy bio and MorphoSys, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 2seventy bio | 0 | 3 | 0 | 0 | 2.00 |
| MorphoSys | 0 | 0 | 0 | 0 | 0.00 |
2seventy bio presently has a consensus price target of $5.00, suggesting a potential upside of 0.00%. Given 2seventy bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe 2seventy bio is more favorable than MorphoSys.
Risk & Volatility
Institutional and Insider Ownership
93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares 2seventy bio and MorphoSys’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 2seventy bio | -207.25% | -53.65% | -23.67% |
| MorphoSys | -226.79% | -694.31% | -22.55% |
Valuation and Earnings
This table compares 2seventy bio and MorphoSys”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 2seventy bio | $48.37 million | 5.50 | -$217.57 million | ($0.10) | -50.00 |
| MorphoSys | $238.28 million | 11.99 | -$205.35 million | ($3.48) | -5.45 |
MorphoSys has higher revenue and earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Summary
2seventy bio beats MorphoSys on 8 of the 13 factors compared between the two stocks.
About 2seventy bio
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
About MorphoSys
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.
